title: The effect of n-3 polyunsaturated fatty acids on leukotriene B₄ and leukotriene B₅ production from stimulated neutrophil granulocytes in patients with chronic kidney disease.
abstract: The proinflammatory leukotriene B₄ (LTB₄) may be of importance in the progression of chronic kidney disease (CKD). We investigated whether n-3 polyunsaturated fatty acids (PUFA) decrease LTB₄ and increase the formation of the less inflammatory leukotriene B₅ (LTB₅) in patients with CKD. Fifty-six patients with CKD stage 2-5 were randomised to 2.4 g n-3 PUFA or olive oil for 8 weeks. Compared to controls, n-3 PUFA significantly decreased release of LTB₄ (p<0.001) and 5-hydroxyeicosatetraenoic acid (5-HETE) (p<0.01) and significantly increased release of LTB₅ (p<0.001) and 5-hydroxyeicosapentaenoic acid (5-HEPE) (p<0.001) from stimulated neutrophil granulocytes. Kidney function evaluated by creatinine clearance and proteinuria did not improve. In conclusion, n-3 PUFA supplementation for 8 weeks in patients with CKD stage 2-5 significantly decreased LTB₄ and 5-HETE and significantly increased LTB₅ and 5-HEPE. No effect was seen on kidney function.
authors.affiliation: Department of Nephrology, Center for Cardiovascular Research Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark.
authors.forename: T
authors.initials: T
authors.lastname: Maaløe
authors.forename: E B
authors.initials: EB
authors.lastname: Schmidt
authors.forename: M
authors.initials: M
authors.lastname: Svensson
authors.forename: I V
authors.initials: IV
authors.lastname: Aardestrup
authors.forename: J H
authors.initials: JH
authors.lastname: Christensen
mesh_terms: D019587:Dietary Supplements / Q000009:adverse effects; D004311:Double-Blind Method; D015536:Down-Regulation; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives* / Q000378:metabolism; D005227:Fatty Acids / Q000032:analysis / Q000097:blood; D015525:Fatty Acids, Omega-3 / Q000009:adverse effects / Q000032:analysis / Q000627:therapeutic use*; D005260:Female; D005395:Fish Oils / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D006098:Granulocytes / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D007975:Leukotriene B4 / Q000031:analogs & derivatives* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D018375:Neutrophil Activation; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism*; D010352:Patient Dropouts; D051436:Renal Insufficiency, Chronic / Q000178:diet therapy* / Q000276:immunology / Q000503:physiopathology; D012720:Severity of Illness Index; D015854:Up-Regulation
chemical_list: D005227:Fatty Acids; D015525:Fatty Acids, Omega-3; D005395:Fish Oils; D007975:Leukotriene B4; C040212:leukotriene B5; D015118:Eicosapentaenoic Acid